<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005978</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067966</org_study_id>
    <secondary_id>P01CA081403</secondary_id>
    <secondary_id>N99-01</secondary_id>
    <nct_id>NCT00005978</nct_id>
  </id_info>
  <brief_title>N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma</brief_title>
  <official_title>Dose Escalation Study of 131 I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma - A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Approaches to Neuroblastoma Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New Approaches to Neuroblastoma Therapy Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor&#xD;
      cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell&#xD;
      or bone marrow transplantation may be able to replace immune cells that were destroyed by&#xD;
      chemotherapy or radiation therapy.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of combination&#xD;
      chemotherapy when given before stem cell transplant and radiation therapy in treating&#xD;
      patients with neuroblastoma that has not responded to previous treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and toxic effects of iodine I 131&#xD;
           metaiodobenzylguanidine (131 I-MIBG) plus ablative doses of carboplatin and etoposide&#xD;
           administered with fixed-dose melphalan followed by autologous hematopoietic stem cell&#xD;
           transplantation in patients with refractory or residual high-risk neuroblastoma.&#xD;
&#xD;
        -  Determine the number of days until blood counts recover in these patients after&#xD;
           receiving this treatment regimen.&#xD;
&#xD;
        -  Determine the response rate to this treatment regimen in these patients.&#xD;
&#xD;
        -  Determine the tumor dosimetry of 131 I-MIBG in patients with measurable soft tissue&#xD;
           lesions.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of iodine I 131 metaiodobenzylguanidine (131&#xD;
      I-MIBG), carboplatin, and etoposide. Patients are stratified according to glomerular&#xD;
      filtration rate (at least 100 mL/min vs 60-99 mL/min).&#xD;
&#xD;
      Patients undergo peripheral blood stem cell harvest or bone marrow harvest at least 2 weeks&#xD;
      prior to treatment with 131 I-MIBG.&#xD;
&#xD;
      Patients receive 131 I-MIBG IV over 120 minutes on day -21; melphalan IV on days -7 to -5;&#xD;
      carboplatin and etoposide IV continuously over 96 hours on days -7 to -4; autologous&#xD;
      hematopoietic stem cell transplantation IV over 15-30 minutes on day 0; and filgrastim&#xD;
      (G-CSF) subcutaneously or IV starting on day 0 and continuing until blood counts recover.&#xD;
      Radiotherapy is administered to the primary tumor site and metastatic sites twice daily for 7&#xD;
      consecutive days within 6 weeks of transplantation or once blood counts have recovered.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of 131 I-MIBG, carboplatin, and etoposide&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at day 84, and then 2 months later if there is a complete response&#xD;
      and/or partial response. Patients who continue therapy on other protocols are followed before&#xD;
      starting the new therapy. All patients are followed for life for any delayed toxic effects&#xD;
      related to study therapy, secondary malignancies, disease status, and survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30-60 patients (15-30 per stratum) will be accrued for this&#xD;
      study within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iobenguane I 131</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of neuroblastoma as evidenced by one of the following:&#xD;
&#xD;
               -  Histological confirmation&#xD;
&#xD;
               -  Demonstrates clumps of tumor cells in bone marrow with elevated urinary&#xD;
                  catecholamine metabolites&#xD;
&#xD;
          -  High-risk refractory or residual disease&#xD;
&#xD;
          -  Poorly responding disease, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Stable disease or partial response after at least 12 weeks of induction therapy&#xD;
&#xD;
               -  Bone marrow containing greater than 100 tumor cells per 100,000 normal cells&#xD;
                  after 12 weeks of induction therapy&#xD;
&#xD;
               -  Progressive disease during or after therapy&#xD;
&#xD;
          -  At least 1 prior positive iodine I 131 metaiodobenzylguanidine (131 I-MIBG) scan since&#xD;
             diagnosis and meets disease status criteria&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  1 to 21 (1 to 20 at diagnosis)&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 500/mm^3&#xD;
&#xD;
          -  Platelet count at least 20,000/mm^3 (transfusion allowed)&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 3 times normal&#xD;
&#xD;
          -  No active hepatitis (for HIV-positive patients only)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Glomerular filtration rate or creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  Creatinine less than 1.5 times normal for age&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction at least 55% OR&#xD;
&#xD;
          -  Fractional shortening at least 30%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No dyspnea at rest or exercise intolerance&#xD;
&#xD;
          -  No requirement for supplemental oxygen&#xD;
&#xD;
          -  No active pneumonia (for HIV-positive patients only)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No disease of any major organ system that would preclude study participation&#xD;
&#xD;
          -  No other active health problems (for HIV-positive patients only)&#xD;
&#xD;
          -  No active infections requiring intravenous antivirals, antibiotics, or antifungals&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  No more than 100 mg/m^2 total dose of prior melphalan&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior total body, whole abdominal, or whole liver irradiation&#xD;
&#xD;
          -  No prior therapy with 131 I-MIBG&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy (6 months for prior radiotherapy to&#xD;
             craniospinal or whole lung fields or greater than 50% of bone marrow space) and&#xD;
             recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior surgical resection allowed&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior myeloablative therapy&#xD;
&#xD;
               -  Prior submyeloablative therapy with peripheral blood stem cell support allowed&#xD;
&#xD;
          -  No concurrent antiretrovirals for HIV-positive patients&#xD;
&#xD;
          -  Concurrent prolonged antifungal allowed if culture and biopsy negative in suspected&#xD;
             residual radiographic lesions&#xD;
&#xD;
          -  No medications that may preclude uptake of 131 I-MIBG for 1 week prior and 2 weeks&#xD;
             after administration of study drugs&#xD;
&#xD;
          -  No concurrent hemodialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine K. Matthay, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006 Jan 20;24(3):500-6. doi: 10.1200/JCO.2005.03.6400.</citation>
    <PMID>16421427</PMID>
  </results_reference>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>December 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2003</study_first_posted>
  <last_update_submitted>October 14, 2010</last_update_submitted>
  <last_update_submitted_qc>October 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Katherine Matthay, MD</name_title>
    <organization>UCSF</organization>
  </responsible_party>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

